Yen Lin Chia

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

David Jayne, Brad H. Rovin, Eduardo Mysler et al. · Annals of the Rheumatic Diseases · 2022 · 177 citations · Full text

The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database

Jarrett Rosenberg, Yen Lin Chia, Sylvia K. Plevritis · Breast Cancer Research and Treatment · 2005 · 151 citations

U.s. Seer Database, Breast Oncology, Cancer Epidemiology +12

A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times

Yanfeng Wang, Yen Lin Chia, Jerry Nedelman et al. · Therapeutic Drug Monitoring · 2009 · 87 citations

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

Ahmad Awada, Agustin A. García, Stephen L. Chan et al. · The Lancet Oncology · 2013 · 82 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +10

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

Ian N Bruce, Alireza Nami, Erik Schwetje et al. · The Lancet Rheumatology · 2020 · 24 citations

Autoimmune Disease, Scleroderma, Systemic Lupus Erythematosus Treatment +13